NCT00662805View on ClinicalTrials.gov

Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD)

CompletedOBSERVATIONAL

Enrollment

762

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Salmeterol/Fluticasone propionate

Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT00662805 - Pharmacovigilance Study to Evaluate Safety of SERETIDE in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter